Wall Street brokerages expect that Merck & Co., Inc. (NYSE:MRK) will post $10.93 billion in sales for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Merck & Co., Inc.’s earnings. The highest sales estimate is $11.05 billion and the lowest is $10.82 billion. Merck & Co., Inc. posted sales of $10.33 billion during the same quarter last year, which would indicate a positive year over year growth rate of 5.8%. The company is expected to announce its next earnings results before the market opens on Thursday, October 25th.

On average, analysts expect that Merck & Co., Inc. will report full year sales of $42.41 billion for the current financial year, with estimates ranging from $42.22 billion to $42.66 billion. For the next year, analysts anticipate that the business will report sales of $43.90 billion, with estimates ranging from $43.79 billion to $43.97 billion. Zacks’ sales calculations are a mean average based on a survey of research analysts that cover Merck & Co., Inc..

Merck & Co., Inc. (NYSE:MRK) last issued its earnings results on Friday, July 27th. The company reported $1.06 earnings per share for the quarter, beating analysts’ consensus estimates of $1.03 by $0.03. The company had revenue of $10.47 billion for the quarter, compared to the consensus estimate of $10.28 billion. Merck & Co., Inc. had a return on equity of 32.68% and a net margin of 3.67%. The firm’s quarterly revenue was up 5.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.01 EPS.

A number of equities analysts have recently weighed in on MRK shares. Morgan Stanley set a $74.00 target price on Merck & Co., Inc. and gave the company a “buy” rating in a report on Thursday, August 23rd. SunTrust Banks reiterated a “buy” rating and issued a $77.00 target price on shares of Merck & Co., Inc. in a report on Thursday, August 16th. Barclays boosted their price target on Merck & Co., Inc. from $70.00 to $75.00 and gave the company an “overweight” rating in a research note on Friday, September 7th. Jefferies Financial Group reissued a “hold” rating and issued a $59.00 price target on shares of Merck & Co., Inc. in a research note on Sunday, July 15th. Finally, BMO Capital Markets reissued a “buy” rating and issued a $70.00 price target on shares of Merck & Co., Inc. in a research note on Sunday, July 22nd. Five research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $69.80.

In other Merck & Co., Inc. news, EVP Adam H. Schechter sold 107,360 shares of the company’s stock in a transaction that occurred on Monday, September 17th. The stock was sold at an average price of $70.18, for a total transaction of $7,534,524.80. Following the completion of the sale, the executive vice president now owns 100,000 shares of the company’s stock, valued at $7,018,000. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Chairman Kenneth C. Frazier sold 228,091 shares of the company’s stock in a transaction that occurred on Tuesday, July 31st. The stock was sold at an average price of $65.00, for a total value of $14,825,915.00. Following the sale, the chairman now directly owns 938,788 shares of the company’s stock, valued at approximately $61,021,220. The disclosure for this sale can be found here. In the last three months, insiders sold 929,360 shares of company stock valued at $64,370,599. 0.32% of the stock is currently owned by company insiders.

Institutional investors have recently made changes to their positions in the business. Rockland Trust Co. bought a new stake in Merck & Co., Inc. during the second quarter worth approximately $3,949,000. Sawyer & Company Inc lifted its holdings in shares of Merck & Co., Inc. by 10.7% during the second quarter. Sawyer & Company Inc now owns 22,984 shares of the company’s stock worth $1,395,000 after buying an additional 2,215 shares during the last quarter. Steward Partners Investment Advisory LLC lifted its holdings in shares of Merck & Co., Inc. by 37.0% during the second quarter. Steward Partners Investment Advisory LLC now owns 122,748 shares of the company’s stock worth $7,451,000 after buying an additional 33,153 shares during the last quarter. HL Financial Services LLC lifted its holdings in shares of Merck & Co., Inc. by 0.7% during the second quarter. HL Financial Services LLC now owns 217,281 shares of the company’s stock worth $13,189,000 after buying an additional 1,540 shares during the last quarter. Finally, Bogart Wealth LLC acquired a new position in shares of Merck & Co., Inc. during the second quarter worth approximately $2,084,000. 72.18% of the stock is owned by hedge funds and other institutional investors.

Shares of MRK opened at $69.81 on Friday. The stock has a market capitalization of $191.27 billion, a PE ratio of 17.54, a price-to-earnings-growth ratio of 2.22 and a beta of 0.81. Merck & Co., Inc. has a fifty-two week low of $52.83 and a fifty-two week high of $72.89. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.04 and a current ratio of 1.33.

The company also recently declared a quarterly dividend, which was paid on Friday, October 5th. Investors of record on Monday, September 17th were paid a $0.48 dividend. The ex-dividend date was Friday, September 14th. This represents a $1.92 annualized dividend and a dividend yield of 2.75%. Merck & Co., Inc.’s payout ratio is 48.24%.

Merck & Co., Inc. Company Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular diseases, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases.

Featured Article: How to interpret a stock’s beta number

Get a free copy of the Zacks research report on Merck & Co., Inc. (MRK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.